Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

US FDA extends review period for Eli Lilly and Incyte’s rheumatoid arthritis treatment

pharmaceutical-technologyJanuary 17, 2017

Tag: Eli Lilly and Incyte’s , Rheumatoid Arthritis

PharmaSources Customer Service